Lexaria Bioscience Corp. Investor Relations Kit

Investment Highlights Patented lipophilic delivery system (DehydraTECH) proven to increase bio-absorption for improved efficacy Patents cover a variety of lipophilic bio-actives, including cannabinoids, nicotine and vitamins Growing portfolio of intellectual property includes 16 patents granted collectively in the US and Australia and 60 patent applications filed across over 40 countries Ability to use DehydraTECH in a variety of markets including nicotine (estimated at C$990 billion), pharmaceuticals (estimated at C$91 billion) and cannabinoids (estimated at C$14 billion)

RkJQdWJsaXNoZXIy NDMyMDk=